Jorge Cortes, EHA 2022: Updates from the QuANTUM-First trial of quizartinib versus placebo plus intensive chemotherapy in FLT3-ITD+ AML
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes one of his main highlights from the 27th Congress of the European Hematology Association (EHA). The phase III QuANTUM-First trial (NCT02668653) assessed quizartinib in relapsed/refractory FLT3–internal tandem duplication positive acute myeloid leukemia. The primary endpoint of the study was overall survival and this showed that treatment with quizartinib reduced the risk of relapse in patients up to 75 years old.
The abstract ‘QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML’ (Abstract S100) was presented at EHA 2022.
Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).
